HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center ...
Jun 3, 2023
0
6
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper understanding of the vast diversity of T cell states as well as their relationships ...
May 29, 2023
0
33
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular ...
May 25, 2023
0
3
In a new study, researchers from The University of Texas MD Anderson Cancer Center have created the largest single-cell atlas of brain metastases from renal cell carcinoma (RCC) with matched primary and extracranial metastases, ...
Apr 18, 2023
0
1
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Apr 18, 2023
0
3
A new study led by researchers at The University of Texas MD Anderson Cancer Center has discovered that co-occurring mutations in three tumor suppressor genes—KEAP1, SMARCA4 and CDKN2A—are linked with poor clinical outcomes ...
Apr 17, 2023
0
5
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), ...
Apr 17, 2023
0
2
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial ...
Apr 17, 2023
0
13
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
4
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from ...
Mar 30, 2023
0
21
